Chinese Academy of Medical Sciences clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 237 studies whose lead sponsor is Chinese Academy of Medical Sciences. 19 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 4, 2022.
Keep track of what changes. Save the Chinese Academy of Medical Sciences studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Focus areas
Conditions Chinese Academy of Medical Sciences leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 237. Browse all 237 →
- A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With ChemoradiotherapyRecruitingNCT04749394Phase 2
- Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal CancerNot yet recruitingNCT05484024Phase 2/3
- How do Super Lean Subjects Keep Resistant to Body Weight Gain?RecruitingNCT03221322
- Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world StudyNot yet recruitingNCT05287308Not applicable
- Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast CancerNot yet recruitingNCT05291910Phase 4
- Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour ResectionEnrolling by invitationNCT04762459Phase 3
- Radiotherapy for Extracranial Oligometastatic Breast CancerRecruitingNCT04646564Phase 3
- The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC PtsRecruitingNCT05074966Phase 3
- Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant ReconstructionRecruitingNCT05045287Not applicable
- Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior TherapiesNot yet recruitingNCT04994626Phase 2
- Optimization of Preoperative Treatment in Locally Advanced Rectal CancerRecruitingNCT02533271Phase 3
- Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT04861467Phase 2
- Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal CarcinomaRecruitingNCT03908372Phase 2/3
- The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic MonitoringRecruitingNCT04499794
- Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCLEnrolling by invitationNCT04491721
- Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant ChemotherapyRecruitingNCT04437160Phase 2
- A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast CancerNot yet recruitingNCT03854617Phase 2
- Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer PatientsRecruitingNCT03731442Phase 3
- Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric CancerAvailableNCT02209441
- HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BCStatus unknownNCT05566457Phase 2
- Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast CancerStatus unknownNCT05546255Phase 2
- Low-dose Radiotherapy in iNHLStatus unknownNCT05543070Phase 2
- AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCCStatus unknownNCT05522894Phase 2
- FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced StageStatus unknownNCT05279677Phase 2
- Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal CancerStatus unknownNCT05016869Phase 1/2
- Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal CancerCompletedNCT02725424Phase 2
- Adjuvant Radiotherapy for pT1b Esophageal Cancer After Submucosal Endoscopic ResectionCompletedNCT05499195
- A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid TumorsStatus unknownNCT05499715Phase 1
- The Clinical Effect of Adaptive Posture-balance Cardiac Rehabilitation Exercise on Cardiovascular DiseasesCompletedNCT05496153Not applicable
- Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 ResectionStatus unknownNCT05460403
- Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI TechnologyStatus unknownNCT05441098
- Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses)Status unknownNCT05216484Phase 3
- Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABCStatus unknownNCT05000736
- Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABCStatus unknownNCT05343117
- A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial CarcinomaStatus unknownNCT05318339Phase 2
- Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04348032Phase 2
- Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04390958Phase 2
- Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world StudyStatus unknownNCT04835324
- Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaStatus unknownNCT04140318Phase 2
- A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal CancerCompletedNCT04247984Phase 2
- Purified Inactivated Japanese Encephalitis VaccineStatus unknownNCT04223037Phase 3
- Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and AboveStatus unknownNCT05163652Phase 3
- Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and AboveStatus unknownNCT05164731Phase 3
- Temozolomide for Injection Combined With Epirubicin in First-line Treatment of LeiomyosarcomaStatus unknownNCT05204524Not applicable
- The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCsStatus unknownNCT05202275Phase 2
- Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in ChinaCompletedNCT05194371
- Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast CancerStatus unknownNCT05089643Phase 2
- Neratinib Dose Escalation Regimen for HER2 Positive Early Breast CancerStatus unknownNCT05154396Phase 2
- Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCLStatus unknownNCT05149170Phase 2
- Characteristics and Treatment Trends of Young Breast Cancer in ChinaStatus unknownNCT05068115